Objective• Acute coronary syndrome (ACS) is a common cardiovascular complication in
patients with type 2 diabetes mellitus (T2DM) and significantly increases the risk of disability …

Background Data about real-world effects of combined therapy with sacubitril/valsartan plus
dapagliflozin in patients affected by heart failure (HF) with reduced ejection fraction (HFrEF) …

Background Dilated cardiomyopathy has an extremely poor prognosis, sacubitril/valsartan
and dapagliflozin are important drugs to improve the prognosis. However, patients with …

The sodium–glucose cotransporter 2 (SGlT2) inhibitor dapagliflozin is safe and does not
increase the rate of adverse cardiovascular events in patients with type 2 diabetes mellitus …

Background: Type II diabetes mellitus and ischemic heart disease (IHD) commonly coexist
and can be dangerous. The sodium glucose cotransporter-II inhibitors (SGLT2i) are a new …

Objective: This study aimed to observe the effect of dapagliflozin on left ventricular ejection
function (LVEF) and left ventricular end‐diastolic volume (LVEDV) in patients with acute …

Objective: Cardiovascular disease remains the leading cause of mortality among patients
with type 2 diabetes mellitus (T2DM). Sodium-glucose co-transporter-2 (SGLT-2) inhibitors is …

Background This study aims at identifying if there is a role for Sodium glucose co-transporter
2 inhibitors (SGLT2i) in the event of acute myocardial infarction. Patients who presented with …

Sodium–glucose cotransporter-2 inhibitors (SGLT2is) are a relatively new class of
antidiabetic drugs that have shown favorable effects in heart failure (HF) patients …

Background Dapagliflozin is a selective SGLT2 inhibitor, which has been widely used in the
treatment of patients with type 2 diabetes mellitus (T2DM). By blocking the reabsorption of …